585 related articles for article (PubMed ID: 16768547)
21. Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
Huo X; Hu Z; Zhai X; Wang Y; Wang S; Wang X; Qin J; Chen W; Jin G; Liu J; Gao J; Wei Q; Wang X; Shen H
Breast Cancer Res Treat; 2007 May; 102(3):329-37. PubMed ID: 17028982
[TBL] [Abstract][Full Text] [Related]
22. A common missense variant in BRCA2 predisposes to early onset breast cancer.
Górski B; Narod SA; Lubinski J
Breast Cancer Res; 2005; 7(6):R1023-7. PubMed ID: 16280055
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
[TBL] [Abstract][Full Text] [Related]
24. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Claus EB; Stowe M; Carter D
Breast Cancer Res Treat; 2003 Mar; 78(1):7-15. PubMed ID: 12611452
[TBL] [Abstract][Full Text] [Related]
25. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
Rafnar T; Benediktsdottir KR; Eldon BJ; Gestsson T; Saemundsson H; Olafsson K; Salvarsdottir A; Steingrimsson E; Thorlacius S
Eur J Cancer; 2004 Dec; 40(18):2788-93. PubMed ID: 15571962
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Claus EB; Petruzella S; Matloff E; Carter D
JAMA; 2005 Feb; 293(8):964-9. PubMed ID: 15728167
[TBL] [Abstract][Full Text] [Related]
27. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
Sauer MK; Andrulis IL
J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
[TBL] [Abstract][Full Text] [Related]
29. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
30. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
31. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
32. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
33. BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
Gorringe KL; Choong DY; Visvader JE; Lindeman GJ; Campbell IG
Breast Cancer Res Treat; 2008 Oct; 111(3):505-9. PubMed ID: 17972171
[TBL] [Abstract][Full Text] [Related]
34. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.
Karppinen SM; Heikkinen K; Rapakko K; Winqvist R
J Med Genet; 2004 Sep; 41(9):e114. PubMed ID: 15342711
[No Abstract] [Full Text] [Related]
35. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Sabatier R; Adélaïde J; Finetti P; Ferrari A; Huiart L; Sobol H; Chaffanet M; Birnbaum D; Bertucci F
Genes Chromosomes Cancer; 2010 Dec; 49(12):1143-51. PubMed ID: 20842729
[TBL] [Abstract][Full Text] [Related]
36. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
Arason A; Jonasdottir A; Barkardottir RB; Bergthorsson JT; Teare MD; Easton DF; Egilsson V
J Med Genet; 1998 Jun; 35(6):446-9. PubMed ID: 9643283
[TBL] [Abstract][Full Text] [Related]
37. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.
Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Durocher F;
J Hum Genet; 2009 Mar; 54(3):152-61. PubMed ID: 19197335
[TBL] [Abstract][Full Text] [Related]
38. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Couch FJ; Sinilnikova O; Vierkant RA; Pankratz VS; Fredericksen ZS; Stoppa-Lyonnet D; Coupier I; Hughes D; Hardouin A; Berthet P; Peock S; Cook M; Baynes C; Hodgson S; Morrison PJ; Porteous ME; Jakubowska A; Lubinski J; Gronwald J; Spurdle AB; ; Schmutzler R; Versmold B; Engel C; Meindl A; Sutter C; Horst J; Schaefer D; Offit K; Kirchhoff T; Andrulis IL; Ilyushik E; Glendon G; Devilee P; Vreeswijk MP; Vasen HF; Borg A; Backenhorn K; Struewing JP; Greene MH; Neuhausen SL; Rebbeck TR; Nathanson K; Domchek S; Wagner T; Garber JE; Szabo C; Zikan M; Foretova L; Olson JE; Sellers TA; Lindor N; Nevanlinna H; Tommiska J; Aittomaki K; Hamann U; Rashid MU; Torres D; Simard J; Durocher F; Guenard F; Lynch HT; Isaacs C; Weitzel J; Olopade OI; Narod S; Daly MB; Godwin AK; Tomlinson G; Easton DF; Chenevix-Trench G; Antoniou AC;
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1416-21. PubMed ID: 17627006
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique.
Gomaa Mogahed SH; Hamed YS; Ibrahim Moursy YE; Mahomoud Saied MH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):431-438. PubMed ID: 32102521
[TBL] [Abstract][Full Text] [Related]
40. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
